|
|
|
The Associated Press INSIDE WASHINGTON: Stream of WH health care visits The Associated Press WASHINGTON — President Barack Obama's top aides met frequently with lobbyists and health care industry heavyweights as his...
That much is known. "Essential metals are at the center of many emerging problems in health, medicine and the environment, and this work opens the door to new biological experiments," said Thomas V. O'Halloran, the study's...
JANUVIA (jah-NEW-vee-ah) is a once-daily prescription pill that, along with diet and exercise, helps lower blood sugar levels in people with type 2 diabetes. Important Information About JANUVIA JANUVIA has not been studied with...
According to recent research published in the Journal of Allergy and Clinical Immunology, "Frequencies of behavior-related adverse experiences (BRAEs) in controlled clinical studies of leukotriene modifier drugs have not been...
According to recent research from the United States, "Compare healthcare utilization and total payments for community-acquired pneumonia (CAP) episodes-of-care among 5 health plan designs spanning the continuum of managed care....
Related topics: Mergers and acquisitions, Industry Drivers US drugmaker Merck & Co is to close a New Jersey warehouse owned by recent acquisition Schering-Plough, cutting 80 jobs. The facility, in Hunterdon County, stores and...
Regulatory News: The Swedish biotech company Karo Bio (Reuters: KARO.ST) today announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration's lead investigational drug...
Merck Serono S APosted on:25 Nov 09 Merck Serono Launches New Website on PhenylketonuriaPR NewswireGENEVA, November 25 GENEVA, November 25 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany,...
Science|Business reporting Merck Serono has announced it is to establish a global R&D centre in Beijing, China, investing more than €150 million and creating 200 new jobs over the next four years. The centre will specialise in...
PROLOR Biotech, Inc., today noted the positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for marketing approval in Europe for ELONVA((R)), a long-acting CTP-modified...
